Explore the Agenda
8:00 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Exploring Next-Gen, Complex Formats to Overcome or Enhance T-Cell Exhaustion, Resistance Mechanisms & Antigen Escape
9:00 am Beyond Bispecifics: Novel Modalities Increase the Therapeutic Window & Durability Of Next-Generation TCEs
- New TCE designs are necessary to crack the code of solid-tumor TCEs and address relapsed/refractory heme malignancies
- Better biological data packages are necessary to design avidity-driven modalities
- CD3 affinity needs to be developed in the context of the modality with more thoughtful clinical dosing regimens
9:30 am Talk Session Reserved for Expertise Partner – ExcellGene
10:00 am Where Design Meets Biology: Engineering Multispecific TCEs & ADCs to Expand Therapeutic Index
- Leveraging combinatorial screening platforms for optimizing multispecific modalities
- Increasing tumor selectivity through novel conditionally active T-cell engagers
- Engineering logic-gated bispecific ADCs for enhanced target coverage or tumor selectivity
10:30 am Morning Refreshments, Networking Break & Scientific Poster Session
11:00 am Beyond ADCs: Payload-Free Tumor Killing Through MUC16-Guided DR5 Superclustering
- Why ADCs hit a ceiling: Payload-driven toxicity narrows therapeutic windows and confines benefit to high-antigen-expressing tumors. Even leading approved programs struggle to reach the moderate- and low-expressing patients who often make up most of the addressable population
- The Cancerlysin™ Solution: Antigen-guided DR5 superclustering. MUC16 binding by IMV-M™ triggers tumor-localized DR5 superclustering and extrinsic apoptotic signaling with no cytotoxic payload. Single-agent regressions in pancreatic, lung, and ovarian xenograft models; clean NHP safety to 4× therapeutic dose with zero hepatotoxicity; projected patient eligibility of 50% in NSCLC and 64–92% in ovarian – multiples over leading DXd-ADCs in the same indications
- A platform built for what comes after ADCs. The Cancerlysin™ platform extends to IMV-C (colorectal, gastric) and IMV-5 (AML); its payload-free architecture is compatible with standard antibody manufacturing – no linker chemistry, no DAR control, no payload-related regulatory burden
11:30 am Talk Session Reserved for Expertise Partner – Catalent
12:00 pm Multi-Specific Engager Proteins with Diverse & Novel Functionalities
- Our Phase 1/2 clinical program solves critical issues confronting CAR-T cell therapies
- Our clinical development programs illustrate how the modularity inherent in our technology broadens the pipeline to solid tumors and AML
- Our unique costimulatory engagers provide an early look at the future of bispecific and multi-specific therapies
12:30 pm Lunch, Networking Break & Scientific Poster Session
1:30 pm Advancing Tetraspecific T-Cell Engagers to the Clinic: Integrating CD3xCD28 Co-Stimulation Within Next-Generation Multispecific Formats
- Leveraging a modular platform capable of incorporating multiple specificities (up to tetraspecific and beyond) to enhance precision targeting and overcome current TCE limitations
- Exploring the integration of CD3 and CD28 within one engager to drive improved T-cell activation, persistence, and therapeutic efficacy versus traditional approaches
- Sharing the journey into first-in-human development of a tetraspecific engager, including design rationale, pathway to Phase I, and key considerations for safety and clinical advancement
Leveraging Mechanistic Modelling Approaches for Dose Selection to Derisk Clinical Development & Elevating the Need for Biomarker-Driven Patient Selection Strategies to Diversify Therapeutic Area Applications
2:00 pm QSP Modeling to Inform Dose & Regimen Selection for TAK-280: A Bi-specific Antibody
- Both QW and BIW dosing led to comparable predicted safety outcome
- Immune cell dynamics reveal the key role of de-sensitization in driving attenuation of cytokine Cmax
2:30 pm Quantitative Systems Pharmacology (QSP) Enables Research & Translation of AMP01, a Novel Next Generation Anti-PD1 Bispecific that Amplifies & Redirects Endogenous IL15 to PD1 High Expressing T-Cells, Maximizing Efficacy & Therapeutic Index
- AMPLIFY•RTM are novel multi-specific biologics that targets and captures endogenous ligands, increasing the concentration of the ligand and extending its half-life, and targets tissue specific antigens, thus redirecting the captured ligand to specific tissues, increasing efficacy, TI, and reducing the likelihood of ADA
- AMP01, Reverb’s lead AMPLIFY•RTM program, is designed to capture and redirect endogenous IL15 to PD1 high expressing T-cells, thus providing PD1 inhibition and targeted IL15 mediated expansion of immune cells to the tumor and tumor microenvironment
- The QSP model accelerated the design and selection of AMP01, a potentially best in class novel bispecific PD1 therapy with targeted lympho proliferative action. The model provided insights into the complexity of IL15 mediated immune cell dynamics and how AMP01 amplifies the effect of endogenous IL-15 in a regulated manner, to better understand safety and efficacy for simulated variability. Early QSP model predictions show that AMP01 has the potential to be a true next generation anti-PD1, with complete PD1 blockade and superior TI and efficacy over competitor therapies tested in silico
3:00 pm Open Speaking Slot for Service Providers
- If you have a solution tailored specifically to the bispecific, multispecific and immune cell engager space, this dedicated speaking slot enables you to showcase your approach through data-driven insights and real-world case studies, equipping delegates with practical scientific learnings on how cutting-edge design strategies are tackling key development challenges
- Interested in partnering with us? Contact sponsor@hansonwade.com to learn how you can secure this speaking slot to showcase your expertise
3:30 pm Afternoon Networking Break
4:00 pm Advancing Tarlatamab in SCLC: From Second-Line Approval to Frontline & Combination Strategies
- Details to be announced
Recognizing the Different Bars for Safety & Efficacy Data for Bispecifics in Oncology versus Autoimmunity/Immunology to Identify Unrealized Market Opportunity
4:30 pm Industry Leaders Panel Discussion:
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology